BIOTECH TARGET N V - 24 May 2021 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Reporting relationship: 10%+ Owner
Issuer ticker: ESPR
Reported as of: 24 May 2021
Net transaction value: +$2,021,620
SEC form: 4
Accepted by SEC: 26 May 2021, 11:53:05 UTC
Prior SEC filing: 21 May 2021
Next SEC filing: 11 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Ivo Betschart

Key filing fact

BIOTECH TARGET N V filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 26 May 2021.

Key facts

This page summarizes BIOTECH TARGET N V's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 May 2021, 11:53.

Change

Previous filing in this sequence was filed on 21 May 2021.
Current net transaction value: +$2,021,620.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ESPR transaction

Common Stock

Purchase

Transaction value: $2,021,620
Shares: +100,000
Change %: +2.3%
Price: $20.22
Shares after: 4,477,964
Date: 24 May 2021
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Biotech Target N.V. is a wholly-owned subsidiary of BB Biotech AG. Accordingly, BB Biotech AG may be deemed to be the indirect beneficial owner of the securities of Esperion Therapeutics, Inc. held directly or indirectly by Biotech Target N.V. This Form 4 is filed jointly by BB Biotech AG and Biotech Target N.V.